Trump says COVID-19 vaccine will ship in 'a matter of weeks' — but excludes New York
FDA has not yet been asked to grant the necessary emergency approvals
Gliding over significant challenges still to come, U.S. President Donald Trump on Friday offered a rosy update on the race for a vaccine for the resurgent coronavirus as he delivered his first public remarks since his defeat by president-elect Joe Biden. He still did not concede the election.
Trump spoke from the Rose Garden as the nation sets records for confirmed cases of COVID-19, and as hospitalizations near critical levels and fatalities climb to the highest levels since the spring.
He said a vaccine would ship in "a matter of weeks" to vulnerable populations, though the Food and Drug Administration has not yet been asked to grant the necessary emergency approvals.
Public health experts worry that Trump's refusal to take aggressive action on the pandemic or to co-ordinate with the Biden team during the final two months of his presidency will only worsen the effects of the virus and hinder the nation's ability to swiftly distribute a vaccine next year.
As states impose new restrictions in the face of rising caseloads, Trump asked all Americans to remain "vigilant." But he ruled out a nationwide "lockdown" and appeared to acknowledge that the decision won't be his much longer.
WATCH | Trump makes closest nod so far to U.S. election result:
"This administration will not be going to a lockdown," he said. "Hopefully whatever happens in the future, who knows, which administration it will be I guess time will tell, but I can tell you this administration will not go to a lockdown."
Biden, for his part, has not endorsed a nationwide shutdown, but he appealed for Trump to take "urgent action" to curtail the spread of the virus.
"The crisis does not respect dates on the calendar, it is accelerating right now," he said in a statement Friday.
Trump said vaccines would "arrive within a few weeks," saying they were ready and merely awaiting approval — and would be given "to high-risk individuals right away."
In fact, there's no guarantee that Pfizer's shot, the front-runner, will get rapid authorization for emergency use.
WATCH | What Pfizer's vaccine trial means for the pandemic:
Even if it does, there's no information yet indicating if the vaccine works in older adults or just younger, healthier adults. Nor does Pfizer have a large commercial stockpile already poised to ship; initial batches of shots would be small and targeted to certain still-to-be-determined populations.
Trump, aiming to settle political scores, said he would not ship vaccines to hard-hit New York until Democratic Gov. Andrew Cuomo signs off, noting that the state has promised to do its own review to ensure their safety.
"The governor will let us know when he's ready," Trump said.
WATCH | Trump singles out New York Gov. Cuomo:
Cuomo pushed back in a CNN interview, saying New York is one of several states that set up their own scientific panels to give residents greater confidence to take the vaccine if it is safe to use. He accused Trump of "politicizing the process."
"As soon as they get us the drug, we are ready to distribute it," Cuomo said.
Meanwhile, his campaign prediction that the U.S. was "rounding the turn" on the pandemic has met a harsh reality, with his own White House becoming the focus of yet another outbreak.
Trump's aggressive travel despite the virus has taken its toll on his protectors as well. The U.S. Secret Service is experiencing a significant number of cases, many believed to be linked to his rallies in the closing days of the campaign, according to one official.
White House press secretary Kayleigh McEnany, meanwhile, said Trump is "not even at that point yet" when it comes to conceding to Biden.
Trump has levelled baseless allegations of widespread voter fraud, even as his own administration has said there is no evidence to support the claims.
His aides suggest he is merely trying to keep his base of supporters on his side in defeat.
WATCH | Stalled presidential transition disrupts U.S. COVID-19 response:
With more than 100,000 new confirmed U.S. cases reported daily for more than a week, Trump has been more focused on tracking the rollout of a vaccine, which won't be widely available for months.
He has fumed that Pfizer intentionally withheld an announcement about progress on its vaccine trial until after Election Day, according to a White House official who was not authorized to publicly comment and spoke on condition of anonymity.
Pfizer said it did not purposely withhold trial results.
The president has consistently played down the pandemic, which has killed more than 240,000 Americans and infected more than 10 million people in the U.S.
WATCH | New Yorkers fear a repeat of COVID-19 situation from the spring:
White House chief of staff Mark Meadows tested positive last week after attending an election night party at the White House.
Others at the party also have tested positive, including White House political director Brian Jack, former White House aide Healy Baumgardner and Trump campaign advisers David Bossie and Corey Lewandowski. Lewandowski said Thursday that he believes he contracted the virus in Philadelphia while assisting the president's election challenge there.
Biden, for his part, largely framed the election as a referendum on Trump's handling of the pandemic. He has made addressing the virus his top priority as he moves forward with his transition.
WATCH | Biden lays out plan to fight COVID-19 pandemic:
He spoke by phone Thursday with House Speaker Nancy Pelosi and Senate Minority Leader Chuck Schumer about the intensifying pandemic and prospects for passage of a COVID-19 relief bill in the lame duck session of Congress.
Incoming White House chief of staff Ron Klain said Biden will appoint a "COVID co-ordinator" who will lead the administration's pandemic response.
Klain, speaking on MSNBC Thursday night, said the individual will have "direct access" to the president and will brief him daily on the pandemic. A team of people under the co-ordinator will supervise vaccine distribution, address supply chain disruptions and improve access to testing.